Coronary, Peripheral, and Neurovascular Guidewires-Performance Tests and Recommended Labeling; Guidance for Industry and Food and Drug Administration Staff; Availability, 54609-54611 [2019-22194]
Download as PDF
Federal Register / Vol. 84, No. 197 / Thursday, October 10, 2019 / Notices
information on electronic access to the
guidance. Submit written requests for a
single hard copy of the guidance
document entitled ‘‘Intravascular
Catheters, Wires, and Delivery Systems
with Lubricious Coatings—Labeling
Considerations’’ to the Office of Policy,
Guidance and Policy Development,
Center for Devices and Radiological
Health, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 66,
Rm. 5431, Silver Spring, MD 20993–
0002. Send one self-addressed adhesive
label to assist that office in processing
your request.
FOR FURTHER INFORMATION CONTACT:
Leigh Anderson, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 2656, Silver Spring,
MD 20993–0002, 301–796–5613.
SUPPLEMENTARY INFORMATION:
I. Background
Hydrophilic and/or hydrophobic
coated devices have been used for more
than 20 years in minimally invasive
diagnostic and therapeutic
cerebrovascular, cardiovascular and
peripheral vascular procedures.
Although these devices may offer
patient benefits, evidence indicates that
the coating may separate from
intravascular devices in some
circumstances. FDA has received and
analyzed information concerning
serious adverse events associated with
hydrophilic and/or hydrophobic
coatings separating (e.g., peeling,
flaking, shedding, delaminating,
sloughing off) from intravascular
medical devices.
FDA has not concluded that any
specific manufacturer or brand of these
devices is associated with higher risks
than others. The cause of coating
separation is multifactorial, and can be
associated with factors including device
design, device manufacturing, and use.
Current FDA analysis suggests that userelated issues may be mitigated through
proper device selection, preparation,
and other labeling considerations that
are addressed within this guidance.
This guidance addresses labeling
considerations for devices containing
lubricious coatings used in the
vasculature. The purpose of this
guidance is to provide
recommendations for information to be
included in the device labeling, as
submitted in PMAs or premarket
notification submissions (510(k)s) for
Class III and Class II devices, to enhance
the consistency of coating information
across these product areas as well as to
promote the safe use of these devices in
the clinical setting.
FDA considered comments received
on the draft guidance that appeared in
the Federal Register of June 15, 2018
(83 FR 27996). FDA revised the
guidance as appropriate in response to
the comments.
II. Significance of Guidance
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the current
thinking of FDA on labeling
considerations for intravascular
catheters, wires, and delivery systems
with lubricious coating. It does not
establish any rights for any person and
is not binding on FDA or the public.
You can use an alternative approach if
it satisfies the requirements of the
applicable statutes and regulations. This
guidance is not subject to Executive
Order 12866.
III. Electronic Access
Persons interested in obtaining a copy
of the guidance may do so by
downloading an electronic copy from
the internet. A search capability for all
Center for Devices and Radiological
Health guidance documents is available
at https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/default.htm. This
guidance is also available at https://
www.regulations.gov. Persons unable to
download an electronic copy of
‘‘Intravascular Catheters, Wires, and
Delivery Systems with Lubricious
Coatings—Labeling Considerations’’
may send an email request to CDRHGuidance@fda.hhs.gov to receive an
electronic copy of the document. Please
use the document number 16016 to
identify the guidance you are
requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information.
These collections of information are
subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3521). The collections
of information in the following FDA
regulations have been approved by OMB
as listed in the following table:
21 CFR part
Topic
807, subpart E .........................................................................
814, subparts A through E .......................................................
801 ...........................................................................................
Premarket Notification .............................................................
Premarket Approval ................................................................
Medical Device Labeling Regulations .....................................
Dated: October 4, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–22192 Filed 10–9–19; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–D–1775]
BILLING CODE 4164–01–P
Coronary, Peripheral, and
Neurovascular Guidewires—
Performance Tests and Recommended
Labeling; Guidance for Industry and
Food and Drug Administration Staff;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
SUMMARY:
VerDate Sep<11>2014
19:50 Oct 09, 2019
Jkt 250001
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
54609
OMB control No.
0910–0120
0910–0231
0910–0485
announcing the availability of a final
guidance entitled ‘‘Coronary, Peripheral,
and Neurovascular Guidewires—
Performance Tests and Recommended
Labeling.’’ This guidance provides
recommendations for the information
and testing that should be included in
premarket submissions for guidewires
intended for use in the coronary
vasculature, peripheral vasculature, and
neurovasculature.
DATES: The announcement of the
guidance is published in the Federal
Register on October 10, 2019.
ADDRESSES: You may submit either
electronic or written comments on
Agency guidances at any time as
follows:
E:\FR\FM\10OCN1.SGM
10OCN1
54610
Federal Register / Vol. 84, No. 197 / Thursday, October 10, 2019 / Notices
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2018–D–1775 for ‘‘Coronary, Peripheral,
and Neurovascular Guidewires—
Performance Tests and Recommended
Labeling.’’ Received comments will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
VerDate Sep<11>2014
19:50 Oct 09, 2019
Jkt 250001
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
An electronic copy of the guidance
document is available for download
from the internet. See the
SUPPLEMENTARY INFORMATION section for
information on electronic access to the
guidance. Submit written requests for a
single hard copy of the guidance
document entitled ‘‘Coronary,
Peripheral, and Neurovascular
Guidewires—Performance Tests and
Recommended Labeling’’ to the Office
of Policy, Guidance and Policy
Development, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5431, Silver Spring,
MD 20993–0002. Send one selfaddressed adhesive label to assist that
office in processing your request.
FOR FURTHER INFORMATION CONTACT:
Nicole Goodsell, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 2309, Silver Spring,
MD 20993–0002, 240–402–6600.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
I. Background
FDA is announcing the availability of
a guidance for industry and FDA staff
entitled ‘‘Coronary, Peripheral, and
Neurovascular Guidewires—
Performance Tests and Recommended
Labeling.’’ This guidance updates and
clarifies performance testing and
labeling recommendations to support a
premarket notification (510(k)
submission) for guidewires intended for
use in the coronary vasculature,
peripheral vasculature, and
neurovasculature. The
recommendations reflect current review
practices and are intended to promote
consistency and facilitate efficient
review of these submissions. This
guidance is also intended to assist
industry in designing and executing
appropriate performance testing to
support a premarket notification and
provides recommendations for content
and labeling to include in the
submission. FDA considered comments
received on the draft guidance that
appeared in the Federal Register of June
15, 2018 (83 FR 27998). FDA revised the
guidance as appropriate in response to
the comments. This guidance
supersedes ‘‘Coronary and
Cerebrovascular Guidewire Guidance,’’
dated January 1995 (available at: https://
www.fda.gov/downloads/
MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/UCM080789.pdf).
II. Significance of Guidance
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the current
thinking of FDA on coronary,
peripheral, and neurovascular
guidewires performance tests and
recommended labeling. It does not
establish any rights for any person and
is not binding on FDA or the public.
You can use an alternative approach if
it satisfies the requirements of the
applicable statutes and regulations. This
guidance is not subject to Executive
Order 12866.
III. Electronic Access
Persons interested in obtaining a copy
of the guidance may do so by
downloading an electronic copy from
the internet. A search capability for all
Center for Devices and Radiological
Health guidance documents is available
at https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/default.htm. This
guidance document is also available at
https://www.regulations.gov. Persons
unable to download an electronic copy
E:\FR\FM\10OCN1.SGM
10OCN1
54611
Federal Register / Vol. 84, No. 197 / Thursday, October 10, 2019 / Notices
of ‘‘Coronary, Peripheral, and
Neurovascular Guidewires—
Performance Tests and Recommended
Labeling’’ may send an email request to
CDRH-Guidance@fda.hhs.gov to receive
an electronic copy of the document.
Please use the document number 16007
to identify the guidance you are
requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information.
These collections of information are
subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3521). The collections
of information in the following FDA
regulations and guidance have been
approved by OMB as listed in the
following table:
21 CFR part; guidance; or FDA form
Topic
807, subpart E .........................................................................
812 ...........................................................................................
‘‘Requests for Feedback on Medical Device Submissions:
The Q-Submission Program and Meetings with Food and
Drug Administration Staff’’.
800, 801, and 809 ....................................................................
820 ...........................................................................................
Premarket notification .............................................................
Investigational Device Exemption ...........................................
Q-submissions .........................................................................
0910–0120
0910–0078
0910–0756
Medical Device Labeling Regulations .....................................
Current Good Manufacturing Practice (CGMP); Quality System (QS) Regulation.
0910–0485
0910–0073
Dated: October 4, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–22194 Filed 10–9–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2019–N–4041]
Advancing the Development of
Pediatric Therapeutics: Pediatric
Clinical Trial Endpoints for Rare
Diseases With a Focus on Pediatric
Patient Perspectives; Public Workshop
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public workshop.
The Office of Pediatric
Therapeutics, Food and Drug
Administration (FDA), is announcing a
public workshop entitled ‘‘Advancing
the Development of Pediatric
Therapeutics (ADEPT 6): Pediatric
Clinical Trial Endpoints for Rare
Diseases with a Focus on Pediatric
Patient Perspectives.’’ The purpose of
this workshop is to discuss pediatric
patient-specific engagement in the
development of clinical trial endpoints
for rare diseases.
DATES: The public workshop will be
held on November 12, 2019, from 8 a.m.
to 4:30 p.m. See the SUPPLEMENTARY
INFORMATION section for registration date
and information.
ADDRESSES: The public workshop will
be held at the FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (Rm.
1503–A), Silver Spring, MD 20993–
0002. Entrance for the public workshop
participants (non-FDA employees) is
SUMMARY:
VerDate Sep<11>2014
19:50 Oct 09, 2019
Jkt 250001
through Building 1, where routine
security check procedures will be
performed. For parking and security
information, please refer to https://
www.fda.gov/AboutFDA/
WorkingatFDA/BuildingsandFacilities/
WhiteOakCampusInformation/
ucm241740.htm.
FOR FURTHER INFORMATION CONTACT:
Terrie L. Crescenzi, Office of Pediatric
Therapeutics, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20993–0002,
301–796–8646, email: terrie.crescenzi@
fda.hhs.gov; or Elizabeth Sanford, Office
of Pediatric Therapeutics, Food and
Drug Administration, 10903 New
Hampshire Ave., Silver Spring, MD
20993–0002, 301–796–8659, email:
elizabeth.sanford@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Patient engagement is critical in the
development of patient-focused study
endpoints that measure clinical benefit
in clinical trials. Asking patients what
aspects of their disease they consider
important to measure is especially
important for rare diseases, given the
lack of established endpoints for many
rare diseases, the small number of
patients available for enrollment in
trials, and the heterogeneity of disease
manifestations (e.g., between patients
and over time). While there is increased
emphasis on incorporating the patient
voice in rare disease drug development
activities, there is an increased need for
pediatric patient-specific engagement
efforts. Pediatric rare disease drug
development would benefit from direct
and early involvement of pediatric
patients and their caregivers in
determining the most relevant and
clinically meaningful endpoints and
outcome assessment tools for use in
clinical trials.
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
OMB control No.
II. Topics for Discussion at the Public
Workshop
In this workshop, FDA will obtain the
pediatric patient perspective on their
disease/condition and what is most
important to consider when designing
rare disease trials. There will also be
discussion regarding patients’ thoughts
on clinical endpoints that are currently
being used in clinical trials, potential
areas of innovation, and how to create
processes that might include pediatric
patients and their caregivers as
collaborators in endpoint development
in early stages of medical product
development (e.g., protocol design). The
morning session will focus on
identifying endpoints that capture
important aspects of how pediatric
patients feel and function. The
afternoon session will focus on steps for
development of clinical outcome
assessment tools for use in pediatric
patient populations and the potential
role of child and youth friendly
technology in endpoint assessments.
III. Participation in the Public
Workshop
Registration: Persons interested in
attending this public workshop must
register online at: https://
www.eventbrite.com/e/adept-6workshop-pediatric-clinical-trialendpoints-for-rare-diseases-registration67523118465 by November 5, 2019. For
those without internet access, please
contact Terrie Crescenzi or Elizabeth
Sanford (see FOR FURTHER INFORMATION
CONTACT) to register.
Registration is free and based on
space availability, with priority given to
early registrants. Onsite registration on
the day of the meeting will be based on
space availability. Registration
information, the agenda, and additional
background materials can be found at
https://wcms-internet.fda.gov/news-
E:\FR\FM\10OCN1.SGM
10OCN1
Agencies
[Federal Register Volume 84, Number 197 (Thursday, October 10, 2019)]
[Notices]
[Pages 54609-54611]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-22194]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2018-D-1775]
Coronary, Peripheral, and Neurovascular Guidewires--Performance
Tests and Recommended Labeling; Guidance for Industry and Food and Drug
Administration Staff; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of a final guidance entitled ``Coronary, Peripheral,
and Neurovascular Guidewires--Performance Tests and Recommended
Labeling.'' This guidance provides recommendations for the information
and testing that should be included in premarket submissions for
guidewires intended for use in the coronary vasculature, peripheral
vasculature, and neurovasculature.
DATES: The announcement of the guidance is published in the Federal
Register on October 10, 2019.
ADDRESSES: You may submit either electronic or written comments on
Agency guidances at any time as follows:
[[Page 54610]]
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2018-D-1775 for ``Coronary, Peripheral, and Neurovascular
Guidewires--Performance Tests and Recommended Labeling.'' Received
comments will be placed in the docket and, except for those submitted
as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
An electronic copy of the guidance document is available for
download from the internet. See the SUPPLEMENTARY INFORMATION section
for information on electronic access to the guidance. Submit written
requests for a single hard copy of the guidance document entitled
``Coronary, Peripheral, and Neurovascular Guidewires--Performance Tests
and Recommended Labeling'' to the Office of Policy, Guidance and Policy
Development, Center for Devices and Radiological Health, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5431, Silver
Spring, MD 20993-0002. Send one self-addressed adhesive label to assist
that office in processing your request.
FOR FURTHER INFORMATION CONTACT: Nicole Goodsell, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 2309, Silver Spring, MD 20993-0002, 240-
402-6600.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of a guidance for industry and
FDA staff entitled ``Coronary, Peripheral, and Neurovascular
Guidewires--Performance Tests and Recommended Labeling.'' This guidance
updates and clarifies performance testing and labeling recommendations
to support a premarket notification (510(k) submission) for guidewires
intended for use in the coronary vasculature, peripheral vasculature,
and neurovasculature. The recommendations reflect current review
practices and are intended to promote consistency and facilitate
efficient review of these submissions. This guidance is also intended
to assist industry in designing and executing appropriate performance
testing to support a premarket notification and provides
recommendations for content and labeling to include in the submission.
FDA considered comments received on the draft guidance that appeared in
the Federal Register of June 15, 2018 (83 FR 27998). FDA revised the
guidance as appropriate in response to the comments. This guidance
supersedes ``Coronary and Cerebrovascular Guidewire Guidance,'' dated
January 1995 (available at: https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM080789.pdf).
II. Significance of Guidance
This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents the
current thinking of FDA on coronary, peripheral, and neurovascular
guidewires performance tests and recommended labeling. It does not
establish any rights for any person and is not binding on FDA or the
public. You can use an alternative approach if it satisfies the
requirements of the applicable statutes and regulations. This guidance
is not subject to Executive Order 12866.
III. Electronic Access
Persons interested in obtaining a copy of the guidance may do so by
downloading an electronic copy from the internet. A search capability
for all Center for Devices and Radiological Health guidance documents
is available at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. This
guidance document is also available at https://www.regulations.gov.
Persons unable to download an electronic copy
[[Page 54611]]
of ``Coronary, Peripheral, and Neurovascular Guidewires--Performance
Tests and Recommended Labeling'' may send an email request to [email protected] to receive an electronic copy of the document.
Please use the document number 16007 to identify the guidance you are
requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously approved collections of
information. These collections of information are subject to review by
the Office of Management and Budget (OMB) under the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501-3521). The collections of information in
the following FDA regulations and guidance have been approved by OMB as
listed in the following table:
------------------------------------------------------------------------
21 CFR part; guidance; or FDA
form Topic OMB control No.
------------------------------------------------------------------------
807, subpart E.................. Premarket 0910-0120
notification.
812............................. Investigational 0910-0078
Device Exemption.
``Requests for Feedback on Q-submissions...... 0910-0756
Medical Device Submissions: The
Q-Submission Program and
Meetings with Food and Drug
Administration Staff''.
800, 801, and 809............... Medical Device 0910-0485
Labeling
Regulations.
820............................. Current Good 0910-0073
Manufacturing
Practice (CGMP);
Quality System
(QS) Regulation.
------------------------------------------------------------------------
Dated: October 4, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-22194 Filed 10-9-19; 8:45 am]
BILLING CODE 4164-01-P